廣州白雲山醫藥集團股份有限公司 董事會議事規則 （經2025年第二次臨時股東會審議通過） 第一章 總則 第一條 為了進一步明確廣州白雲山醫藥集團股份有限公司（以下簡稱「公司」或「本公司」）董事 會的職權範圍，規範董事會內部機構及運作程序，確保董事會的工作效率和科學決策，充分發揮董 事會的經營決策中心作用，根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《中華人民共和 國證券法》（以下簡稱「《證券法》」）、《上市公司治理準則》《廣州白雲山醫藥集團股份有限公司章程》 （以下簡稱「公司章程」）及其他境內外有關法律、行政法規規定，制定本規則。 第二章 董事 第二條 董事的任職資格： 1 （一）董事為自然人，董事無需持有公司股份； （二）符合國家法律、行政法規、上市所在地證券監督管理機構或者證券交易所相關規定及其他 有關規定。 第三條 有下列情形之一者，不得擔任公司的董事： （一）無民事行為能力或者限制民事行為能力； （二）因貪污、賄賂、侵佔財產、挪用財產或者破壞社會主義市場經濟秩序，被判處刑罰，或因 犯罪被剝奪政治權利，執行期滿未逾五年，被宣告緩刑的，自緩刑考驗期滿之日起未逾二 年； （三）擔任破產清算的公司 ...

廣州白雲山醫藥集團股份有限公司 股東會議事規則 （經2025年第二次臨時股東會審議通過） 第一章 總則 第一條 為提高股東會議事效率，保證股東會會議程序及決議的合法性，充分維護全體股東的 合法權益，根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《中華人民共和國證券法》（以下 簡稱「《證券法》」）、《上市公司股東會規則》《上市公司治理準則》《廣州白雲山醫藥集團股份有限公司 章程》（以下簡稱「《公司章程》」）及境內外其他有關法律、行政法規、上市所在地證券監督管理機構或 者證券交易所相關規定，制定本議事規則。 第二條 廣州白雲山醫藥集團股份有限公司（以下簡稱「本公司」或「公司」）股東會的召集、提 案、通知、召開等事項適用本議事規則。 第三條 本公司應當嚴格按照法律、行政法規、上市所在地證券監督管理機構或者證券交易所 相關規定、《公司章程》及本議事規則的相關規定召開股東會，保證股東能夠依法行使權利。股東會 應當在《公司法》和《公司章程》規定的範圍內行使職權。 本公司董事會應當切實履行職責，認真、按時組織股東會。本公司全體董事應當勤勉盡責，確 保股東會正常召開和依法行使職權。 第二章 股東會職權 1 第五條 ...

| 第一章 | 總則 | 2 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份和註冊資本 | 5 | | 第四章 | 減資和回購股份 | 9 | | 第五章 | 股票和股東名冊 | 11 | | 第六章 | 股東的權利和義務 | 12 | | 第七章 | 股東會 | 18 | | 第八章 | 類別股東表決的特別程序 | 37 | | 第九章 | 董事會 | 40 | | 第十章 | 公司董事會秘書 | 51 | | 第十一章 | 公司總經理及副總經理 | 52 | | 第十二章 | 公司董事和高級管理人員的資格和義務 | 53 | | 第十三章 | 財務會計制度 | 57 | | 第十四章 | 利潤分配 | 57 | | 第十五章 | 內部審計 | 62 | | 第十六章 | 會計師事務所的聘任 | 63 | | 第十七章 | 保險 | 63 | | 第十八章 | 勞動管理和職工工會組織 | 64 | | 第十九章 | 公司的合併與分立 | 65 | | 第二十章 | 公司解散和清算 | 66 | | 第二十一章 | 公司章程的修訂程序 | 68 | ...

（於中華人民共和國註冊成立之股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （H股股份代碼：00874） 於2025年9月26日舉行之2025年第二次臨時股東大會之投票結果 董事會欣然宣佈臨時股東大會已於2025年9月26日（星期五）舉行，且所有提交股東審議和批准之 議案經由有權出席臨時股東大會並於會上投票之股東投票表決後均已獲正式通過。 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）(i)一份日期為2025年9月5日之關於召開2025年 第二次臨時股東大會（「臨時股東大會」）的通告；及(ii)一份日期為2025年9月5日之臨時股東大會通函 （「通函」）。除非文義另有所指外，否則本公告所用詞彙的涵義與通函所界定者相同。 董事會欣然宣佈臨時股東大會已於2025年9月26日（星期五）舉行，且所有提交股東審議和批准之議案 經由有權出席臨時股東大會並於會上投票之股東投票表決後均已獲正式通過。 1. 緒言 1 (1) 臨時股東大會已於202 ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]

核药（RDC）全称放射性药物，是指含有放射性同位素、用于疾病诊断、治疗或医学研究的特殊药 物。核药正革命性地改变着疾病的诊疗方式，也是各国生物医药产业竞相布局的战略高地。当前，全球 十大制药企业已相继进入该赛道，纷纷布局治疗用放射性核素偶联药物的研发。 成立不久，白云山稀核健康技术团队便在哈尔滨医科大学附属第四医院利用自主研发的先进国产固体靶 系统，成功实现了锆-89的高质量制备，填补了国内空白。 本报讯 （记者王镜茹）今年8月，广州医药集团有限公司（以下简称"广药集团"）同厦门稀土所成果转 化平台，共同出资成立广州白云山（600332）稀核健康医药有限公司（以下简称"白云山稀核健康"）， 正式宣告将全面布局核药新赛道。 目前，广药集团已制定清晰目标：短期基于自主开发的"固体靶"技术，快速产业化稀土诊断、治疗型核 素产品；中期计划建设基于中高能加速器的核素生产研发基地，推动新型α治疗核素研发与规模化生 产，并布局多条RDC研发管线；长期则致力于提供具有广药集团特色的智慧核医疗解决方案。 近年来，为支持核医疗产业发展，国家相继出台《医用同位素中长期发展规划（2021—2035年）》等顶 层设计，明确支持技术研发 ...

Core Viewpoint - Guangzhou Pharmaceutical Group is strategically entering the nuclear medicine sector by establishing a joint venture focused on radiopharmaceuticals, aiming to capitalize on the rapidly growing market and technological advancements in this field [1][2][3]. Industry Overview - Radiopharmaceuticals (RDC) are specialized drugs containing radioactive isotopes used for disease diagnosis, treatment, or research, representing a revolutionary shift in medical diagnostics and treatment [2]. - The global therapeutic radiopharmaceutical market is experiencing a compound annual growth rate (CAGR) of nearly 40%, with China's growth rate consistently exceeding 15%, projecting the overall market size to reach trillions [2]. - The Chinese government has introduced policies to support the nuclear medicine industry, including the "Medium and Long-term Development Plan for Medical Isotopes (2021-2035)," which encourages technological innovation and the establishment of special funds [2]. Company Initiatives - Guangzhou Pharmaceutical Group, in collaboration with Xiamen Rare Earth Research Institute, established Guangzhou Baiyunshan Rare Nuclear Health Pharmaceutical Co., marking its official entry into the nuclear medicine sector [1][3]. - The company has signed a strategic agreement with advanced energy laboratories and research institutes to focus on technological innovation and overcoming key technical bottlenecks in radiopharmaceutical development [3][4]. - The newly formed company has successfully developed a solid target system for the high-quality production of Zirconium-89, filling a domestic gap and establishing a foundation for future research [4]. Strategic Partnerships - The joint venture has engaged in collaborations with various top medical institutions to foster industry-academia-research cooperation, aiming to create a closed-loop system for research, production, and application [4]. - A strategic framework agreement was signed with Guangdong Cyclotron Pharmaceutical, focusing on the high-quality, large-scale domestic production of key medical isotopes, reducing reliance on imports [5]. Future Goals - The company has outlined short, medium, and long-term objectives, including the rapid industrialization of rare earth diagnostic and therapeutic isotopes, the establishment of a nuclear isotope production research base, and the development of innovative nuclear medicine solutions [5][6].

Core Viewpoint - The "2025 Phoenix Star Listed Company Awards" ceremony was held in Guangzhou, recognizing companies for their performance in innovation, returns, responsibility, growth, brand influence, and globalization [1] Award Categories and Winners - The awards included categories such as Best Innovative Listed Company, Best Shareholder Return Listed Company, Most Socially Responsible Listed Company, Best Employer Award, Most Growth Potential Listed Company, Most Brand Influential Listed Company, Best Global Business Contribution Listed Company, Best Overseas Globalization Case, and Best IPO Company [1] - Six companies were awarded the title of "Most Brand Influential Listed Company": China Railway Construction Corporation, China Pacific Insurance, Guangzhou Baiyunshan Pharmaceutical, Yiling Pharmaceutical, Master Kong, and Haier Smart Home [1][3] Company Highlights - **China Railway Construction Corporation**: Recognized for its significant role in the "Belt and Road" initiative, operating in over 140 countries, and has been listed among the Fortune Global 500 for 19 consecutive years. The company emphasizes high-quality development and innovation in infrastructure [5][6] - **Master Kong**: Acknowledged for its long-term respect for consumers and commitment to quality. The company aims to promote Chinese culinary culture globally while focusing on technological upgrades and cultural heritage [8][9] - **China Pacific Insurance**: The company has a strong brand value and influence, providing comprehensive protection to 180 million customers. It has been ranked among the top five global insurance brands for several years [11] - **Guangzhou Baiyunshan Pharmaceutical**: As a World Fortune 500 company, it emphasizes high-quality products and social responsibility, with a brand value of 31.79 billion yuan, leading the pharmaceutical health sector in China [13] - **Haier Smart Home**: Transitioned from a home appliance leader to a smart living pioneer, serving over 1 billion users globally. The company focuses on technological innovation and sustainable development, holding the highest number of smart home invention patents for 13 consecutive years [15][16] - **Yiling Pharmaceutical**: Known for its innovative traditional Chinese medicine products, with 17 patented drugs, 11 of which are included in the national medical insurance directory. The company has successfully expanded its market presence in over 50 countries [17][18]

Group 1 - Qianyu Medical's shareholder QM5 LIMITED plans to transfer approximately 6.6693 million shares, accounting for 2% of the company's total share capital [1] - Guizhou Platinum Industry intends to raise no more than 1.291 billion yuan for technological innovation platform construction, industrial transformation, and working capital [1] - Guangdong Construction has won a bid for the Guangzhou Financial City East District project with a contract value of 1.924 billion yuan [1] Group 2 - Sanfu New Science plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 15 million yuan [3] - Baiyun Mountain's subsidiary has entered the II phase of clinical trials for children's Xiao Chai Hu granules, aimed at treating pediatric gastrointestinal colds [4] - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information for market promotion and operation rights in mainland China [5] Group 3 - Daotong Technology plans to transfer 46% of its stake in Saifang Technology for a total consideration of 109 million yuan [7] - Rizhao Port's shareholder Shandong Energy Group intends to reduce its stake by up to 3% [8] - Saiwei Electronics reports that the National Integrated Circuit Fund has reduced its stake by 6.3481 million shares, representing 0.87% of the total share capital [10] Group 4 - Changji Logistics proposes a cash dividend of 0.31 yuan per share for the 2025 interim period [11] - Xuelong Group's shareholder plans to reduce its stake by up to 1.95% [13] - Lianxiang Co. plans to reduce its stake by a total of 3.74% [15] Group 5 - Yingfeite's actual controller plans to reduce its stake by up to 2.82% [16] - Baolong Technology's director plans to reduce his stake by up to 0.11% [17] - China Electric Research's shareholder plans to transfer 2% of the company's shares through an inquiry transfer [18] Group 6 - Oriental Pearl plans to participate in establishing an investment fund with a total fundraising scale of 714 million yuan [19] - Tianqin Equipment's shareholder plans to reduce its stake by up to 1% [21] - Crystal Optoelectronics' shareholder plans to reduce its stake by up to 0.99% [22] Group 7 - Changchun Technology expects a net profit increase of 131.39% to 145.38% for the first three quarters of 2025 [22] - Jinhai Tong's shareholder plans to reduce its stake by up to 1% [24] - Zhongdian Electric's shareholder plans to reduce its stake by up to 3% [26] Group 8 - Zhixiang Jintai has signed exclusive cooperation agreements for two monoclonal antibody injections [27] - Chuangli Group's director plans to reduce his stake by up to 0.7% [28] - Henghui Security's shareholders plan to reduce their stake by a total of 2.34% [29] Group 9 - Tianci Materials' subsidiary has signed a supply cooperation agreement for no less than 800,000 tons of electrolyte products [29] - Tianci Materials has submitted an application for H-share listing on the Hong Kong Stock Exchange [30] - Zhongke Haixun has signed a strategic cooperation agreement with Beibu Gulf Port Group [30] Group 10 - China CNR has elected Sun Yongcai as the chairman of the board [31] - Baiwei Storage plans to issue H-shares and list on the Hong Kong Stock Exchange [32] - Shengxin Lithium Energy plans to acquire a 21% stake in Qicheng Mining for 1.456 billion yuan [33] Group 11 - Zhongjing Electronics plans to raise no more than 700 million yuan for various projects [35] - Dingxin Communications clarifies that its technology authorization from Pingtouge is unrelated to AI intelligent reasoning chips [37] - Rihai Intelligent's major shareholder plans to reduce its stake by up to 2.77% [38] Group 12 - Rihai Optical's actual controller plans to reduce his stake by up to 3% [39] - Xilong Science's actual controllers plan to reduce their stake by a total of 3% [40] - Honggong Technology plans to sign a project contract with a maximum investment of 450 million yuan [41] Group 13 - Mankang Pharmaceutical has signed a strategic cooperation agreement with Nanjing Haijing Pharmaceutical [42] - Mankang Pharmaceutical plans to raise no more than 1.033 billion yuan through a private placement [42] - Kaidi Co.'s shareholder plans to reduce its stake by up to 38,030 shares [43] Group 14 - Hesheng Co. has launched a stock option and restricted stock incentive plan totaling 3.6 million shares [44] - ST Yigou's shareholder plans to reduce its stake by up to 2.85% [46] - Jinziham's subsidiary plans to invest up to 300 million yuan in Zhongzheng Microelectronics [49]

（文章来源：证券日报） 证券日报网讯 9月22日晚间，白云山发布公告称，公司子公司广州白云山光华制药股份有限公司研发的 儿童小柴胡颗粒于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了Ⅱ期临床试验登 记信息。 ...